Human antibodies and binding fragments thereof to tenascin

Human antibodies and binding fragments targeting the FBG domain of tenascin-C address the challenge of chronic inflammation by inhibiting TLR4 signaling, offering therapeutic benefits for conditions like rheumatoid arthritis with enhanced affinity and reduced immunogenicity.

CA3013168CActive Publication Date: 2026-09-22STERLING IP LTD
0 Cites 0 Cited by

Patent Information

Application Number
CA3013168
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-02-10
Filing Date
2017-02-10
Publication Date
2026-09-22
Estimated Expiration
2037-02-10

AI Technical Summary

Technical Problem

Current treatments for chronic inflammatory conditions, such as rheumatoid arthritis, are limited in effectively targeting the biological activity of tenascin-C, an ECM protein that activates TLR4 and promotes inflammation, due to its transient expression in acute inflammation and persistent expression in chronic inflammation.

Method used

Development of human antibodies and binding fragments with high affinity for the fibrinogen-like globe (FBG) domain of tenascin-C, designed to neutralize its biological activity by inhibiting TLR4 signaling and reducing immunogenicity through modification of a potential T cell epitope in the light chain framework.

Benefits of technology

The antibodies and fragments effectively down-regulate tenascin-C activity, providing therapeutic benefits for chronic inflammatory disorders by inhibiting TLR4 activation and reducing inflammation, with improved affinity and reduced immunogenicity compared to parent antibodies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates fully antibodies and binding fragments, to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to composition comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and / or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making said antibodies.
Need to check novelty before this filing date? Find Prior Art